AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06606613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraurethral injection
Description: Procedure: Intraurethral injection~Patients are positioned in the lithotomy position during the procedure. General and/or local anesthesia is administered depending on the investigator\&amp;amp;#39;s preference. An applicator developed for intraurethral injection will be used. This device comprises a holder that is placed into and fixates the urethra (i.e., it distends the urethral circumference, thus smoothing out the longitudinal folds), allowing the use of four syringes to inject cross-linked hyaluronic acid/dextranomer at approximately the 2, 4, 8, and 10 o'clock positions.~Drug: Cross-linked hyaluronic acid/dextranomer
Study NCT06606613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-urethral sling
Description: Procedure: Starting with the dorsal lithotomy position, a foley catheter is inserted to the urethra. Starting with 1-1.5 cm below the urethral meatus, a 1.5-2 cm vertical incision is made. Following the dissection of anterior vaginal mucosa, pubocervical fascia should be dissected sharply .~Dissection is continued laterally to the ischiopubic ramus. Starting downwards from the tendinous insertion of the adductor longus muscle at the level of clitoris, a 1cm incision is made close to the bone. The needle is placed in to the incision and passed medially through the obturator membrane. It has to be considered that the needle is passed very close to the bone in order not to damage the obturator vessel-nerve bundle. With the guidance of the opposite hand's index finger in the vaginal incision the tip of the needle has to be palpated afterwards passing with a 45-degree angle rotation. The next manoeuvre is passing the tip of the needle beside the urethra through the vaginal incision .
Study NCT06613750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Gliclazide
Description: Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks
Study NCT04990947 — intervention group
Intervention type: OTHER
Intervention: lifestyle / RYGB
Description: No intervention, just 2 different groups will be included
Study NCT06613750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
Study NCT06612554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc acetate
Description: Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).
Study NCT06612554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks
Study NCT06614010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection
Description: Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.
Study NCT06614010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Dexmedetomidine
Description: Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
Study NCT06614010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
Study NCT06614140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors
Description: This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect.
Study NCT06613607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Strengthening
Description: Strengthening protocol will comprise of following three phases:~Warm up phase Following exercise would be performed in warm up; Scissor skier, Criss cross crunches, , Hip circles, Bent over twist.~Strengthening:~Abdominal bracing Bracing with heel slides Bracing with leg lifts Bracing with bridging Quadruped alternate arm and leg lifts with bracing Side support with knees flexed Cool down phase: Following exercise would be performed for cood down: Child's pose, Cat cow stretch, Lower back stretch, Obliques stretch
Study NCT06613438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eGERD device
Description: The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user.
Study NCT06613438 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eGERD_Sham
Description: The eGERD_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD_Sham is identical to the eGERD device.
Study NCT06615193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM2005
Description: HDM2005 will be administered via IV infusion.
Study NCT06613997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400mg
Description: Albendazole 400mg per days for 21 consecutive days
Study NCT06613997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 21 consecutive days
Study NCT05716399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric stimulation pretreatment
Description: Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
Study NCT05716399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous acupoint electrical stimulation treatment
Description: Transcutaneous acupoint electrical stimulation treatment
Study NCT05716399 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous acupoint pseudo electric stimulation
Description: Transcutaneous acupoint pseudo electric stimulation
Study NCT04755231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Presbyopia Correcting IOL
Description: UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
Study NCT04755231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
Study NCT06617455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06431581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-Health intervention (educational video, SMS and reminder phone call)
Description: Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
Study NCT06640699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
Study NCT06640699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
Study NCT06617455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Given PO
Study NCT06617455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT06637618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: up front use of mineralocorticoid receptor antagonist
Description: the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
Study NCT06637618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: up front use of mineralocorticoid receptor antagonist
Description: the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
Study NCT06136403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deucravacitinib
Description: treatment by deucravacitinib in two phases of challenge
Study NCT05333588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: The autologous TILs will be intravenous infused into patients.
Study NCT06617455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06617455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03088111 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of samples
Description: To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
Study NCT03088111 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Obiltoxaximab
Description: Obiltoxaximab standard of care
Study NCT05625893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBT and atezolizumab/bevacizumab
Description: Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies.
Study NCT06286358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kinocardiography
Description: Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
Study NCT04768725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention combined with physical-cognitive exergaming
Description: Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
Study NCT04768725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].
Study NCT04768725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical-cognitive intervention
Description: Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
Study NCT06451263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
Study NCT04627025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apraglutide
Description: Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Study NCT06614088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum calprotectin
Description: A blood sample is collected at time of admission to detect serum level of calprotectin
Study NCT06614634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remotely supervised exercise at home or outdoors
Description: Aerobic and strengthening exercise program at home/outdoors at least three days a week for four weeks using a Polar H9 heart rate monitor and elastic band.
Study NCT06614634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based exercise program
Description: The aerobic and strengthening exercise program three days a week for four weeks under supervision in our cardiopulmonary rehabilitation unit.
Study NCT06614634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular risk modification
Description: Psychosocial support for physical activity counselling, heart-healthy diet, referral for smoking cessation and stress management.
Study NCT04627025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apraglutide
Description: Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Study NCT06614634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk modification
Description: Psychosocial support for physical activity counselling, heart-healthy diet, referral for smoking cessation and stress management.
Study NCT06614634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls with reinforcement feedback
Description: Calls once a week that include symptom inquiries and encouraging feedback on exercise logs.
Study NCT05635669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral acupoints acupuncture
Description: Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
Study NCT05635669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal acupoints acupuncture
Description: Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
Study NCT05635669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating acupoints acupuncture
Description: Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
Study NCT05531370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Retraining
Description: Conforming the real-world setting, all participants will continue standard asthma care, i.e., acute and planned visits at GP or pulmonologist.~BR aims to normalize the inhaled volume, nasal inhalation, exhalation to the resting position of the chest (functional residual capacity, FRC), use of the diaphragm muscle, and to move lower parts of the chest in a frequency of 12-16 per minute. This pattern is initially trained in rest (e.g., side lying or sitting), then during physical activity (e.g., walking). Uncontrolled coughing, frequent yawning or sighing is handled by a suppression technique. Relaxation technique is introduced as a separate activity but to be combined with the breathing pattern method to be used in both resting and as possible during physical activity.
Study NCT06453109 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: low intensity focused ultrasound (LIFU)
Description: Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
Study NCT05189379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Alcoholic Odour
Description: A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
Study NCT05189379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcoholic Odour
Description: Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
Study NCT05189379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Alcoholic Images
Description: Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour